N,N-dimethyl-3-(pyridin-3-yl)prop-2-en-1-amine | 228271-76-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N,N-dimethyl-3-(pyridin-3-yl)prop-2-en-1-amine
• 英文别名: (E)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine
• CAS: 228271-76-9
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: WHTPPBOYBAUQJK-GQCTYLIASA-N

物化性质

• 沸点：
  255.2±28.0 °C(Predicted)
• 密度：
  0.989±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-3-(pyridin-3-yl)prop-2-en-1-amine 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 生成 1-(3-Pyridyl)-3-dimethylamino-propan
  参考文献：
  名称：

  阳离子两亲模型化合物的合成，药理和生物物理表征以及膜相互作用QSAR分析。

  摘要：

  阳离子两亲药物具有与生物中间相相互作用的倾向。这项研究的目的是更深入地了解控制这种相互作用的卡两性药物的分子特性。合成了一系列苯丙胺模型化合物，其中在分子的芳族部分引入了修饰。从磷脂酰丝氨酸单层的（45）Ca（2+）替换用于监测药物与磷脂的结合。测量对二棕榈酰磷脂酸脂质体的相变温度的影响，以评估药物对磷脂组装体的结构组织的干扰作用。在豚鼠心脏的Langendorff制剂中测定化合物的抗心律不齐活性以评估膜稳定作用。使用分子内和分子间QSAR描述符开发了这些终点的定量构效关系（QSAR）模型。分子间膜相互作用描述符是从模型磷脂单层化合物的分子动力学模拟中得出的。使用偏最小二乘回归（PLS）和遗传算法工具，即遗传函数近似（GFA），为所有端点导出了QSAR模型。膜相互作用描述符在解释化合物对DPPA脂质体的相变温度的影响方面似乎特别重要，而其他端点可以通过分子内描述符进行适当建模。磷脂酰丝氨酸

  DOI：

  10.1021/jm980694a
• 作为产物：
  描述：

  (2E)-3-(3-吡啶基)-2-丙烯-1-醇 在 氯化亚砜 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 1.0h， 生成 N,N-dimethyl-3-(pyridin-3-yl)prop-2-en-1-amine
  参考文献：
  名称：

  Synthesis and binding of 6,7,8,9-tetrahydro-5H-pyrido[3,4-d]azepine and related ring-opened analogs at central nicotinic receptors

  摘要：

  6,7,8,9-Tetrahydro-5H-pyrido[3,4-d]azepine (5a) and its N-7-methyl derivative 5b were synthesized and evaluated as potential nicotinic acetylcholinergic receptor (nAChR) ligands. On the basis that 6,7,8,9-tetrahydro-5H-pyrido[3,4-c]azepine (4a), which binds at nAChRs with low affinity (K-i = 1100 nM), possesses an internitrogen distance (4.6 Angstrom) that may be less than optimal, we designed compound 5a due to its similar shape but longer internitrogen distance (5.5 Angstrom). Compound 5a (K-i = 45 nM) was found to bind with enhanced affinity. However, unlike what is seen with nornicotine/nicotine, N-methylation of 5a reduced affinity (5b; K-i = 268 nM) rather than enhancing it. The results suggest that 5 may interact at nicotine receptors in a manner that is somewhat different from that of nicotine. Ring-opening of the pyrido[3,4-d]azepine ring led to a series of 3-(2-aminoethyl)pyridines 21 that retained the affinity of the cyclic compound. Subsequent modification, including further chain lengthening (e.g. aminopropylpyridines 22) and introduction of unsaturation, ultimately led to the development of a series of 3-(2-aminethoxy)pyridines 27. Simple N-substituted derivatives of 27 were found to bind with K-i values of 20 to 35 nM. Because parallel structural changes in several series of related compounds did not result in parallel shifts in nAChR affinity, it is unlikely that all the investigated compounds bind in a similar fashion at these receptors. Nevertheless, some of these compounds represent novel classes of nAChR ligands. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80051-8

文献信息

• METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS
  申请人：DUKE UNIVERSITY

  公开号：EP1746985A2

  公开（公告）日：2007-01-31
• SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES
  申请人：Duke University

  公开号：EP2629615A1

  公开（公告）日：2013-08-28
• US7517908B2
  申请人：——

  公开号：US7517908B2

  公开（公告）日：2009-04-14
• [EN] NOVEL HALOPHENYL-PYRIDYL-ALLYLAMINE DERIVATIVES
  申请人：——

  公开号：WO1981001407A1

  公开（公告）日：1981-05-28

  (EN) Compounds of the formula (FORMULA) wherein R is H or CH3, n is 1 or 2 and X is F, Cl, Br, I bound in an optional position to the phenyl group, provided that when X is Br it is bound in a position other than the 4 position, processes for their preparation and pharmaceutical preparations, methods of treatment employing such compounds, The compounds are useful for therapeutic treatment of various kinds of depressive conditions. (FR) Composes de formule: (FORMULE) ou R represente H ou CH3, n vaut 1 ou 2 et X represente F, Cl, Br, I lie dans une position a choix au groupe phenyl, a condition que lorsque X represente Br, il soit lie dans une position autre que la position4; procedes pour leur preparation et preparations pharmaceutiques, et methodes de traitement utilisant de tels composes. Les composes sont utiles pour le traitement therapeutique de divers types d"etats depressifs.
• [EN] METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS<br/>[FR] PROCEDE DESTINE A AUGMENTER LES EFFETS DES INHIBITEURS DE LA REABSORPTION DE LA SEROTONINE
  申请人：UNIV DUKE

  公开号：WO2005112906A2

  公开（公告）日：2005-12-01

  A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enhancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse.